TVTX250117P12500
- 0.09
- 0.000.00%
Travere Therapeutic Newsroom
Wedbush Maintains Travere Therapeutic(TVTX.US) With Buy Rating, Raises Target Price to $26
Wedbush Lifts Price Target on Travere Therapeutics to $26 From $25, Keeps Outperform Rating
Evercore Maintains Travere Therapeutic(TVTX.US) With Buy Rating, Maintains Target Price $33
Evercore Maintains Travere Therapeutic(TVTX.US) With Buy Rating, Maintains Target Price $33
Travere Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Travere Therapeutics Analyst Ratings
H.C. Wainwright Maintains Travere Therapeutic(TVTX.US) With Buy Rating, Raises Target Price to $22
BofA Securities Maintains Travere Therapeutic(TVTX.US) With Buy Rating, Maintains Target Price $24
Guggenheim Maintains Travere Therapeutic(TVTX.US) With Buy Rating, Raises Target Price to $45
Stifel Maintains Travere Therapeutic(TVTX.US) With Hold Rating
BofA Securities Maintains Travere Therapeutic(TVTX.US) With Buy Rating, Maintains Target Price $24
Cantor Fitzgerald Initiates Travere Therapeutic(TVTX.US) With Buy Rating
BofA Securities Maintains Travere Therapeutic(TVTX.US) With Buy Rating, Announces Target Price $24
Stifel Maintains Travere Therapeutic(TVTX.US) With Hold Rating, Raises Target Price to $18
Travere Therapeutics (TVTX) Gets a Buy From J.P. Morgan
Travere Therapeutics Is Maintained at Neutral by Piper Sandler
Travere Therapeutics Analyst Ratings
Piper Sandler Maintains Travere Therapeutic(TVTX.US) With Hold Rating, Raises Target Price to $22
Piper Sandler Reaffirms Their Hold Rating on Travere Therapeutics (TVTX)
TD Cowen Maintains Travere Therapeutic(TVTX.US) With Buy Rating, Maintains Target Price $20